You obviously don't grasp any details. The Pfizer phase III study in reality did not show any effect because they kicked out 200 sick people. Pfizer had illegal access to patient records.
If you would do the same study during a non pandemic phase, then the numbers for Pfizer could be more or less OK.
We now very well understand that the Pfizer vaccine so far did cause between 50..100'000 extra CoV-19 deaths. In Israel the number of CoV-19 cases did increase exponentially after starting the first vaccination phase. The same happened during the down turn (lock down!!), when they started vaccination of younger. A giant bump in cases.
Thanks for this - let us consider your points one by one.
(1) Context. Whatever the evidence from israel - that from the UK (which i know) is indisputable. At the point that we had vaccinated 20% of the most vulnerable we could track the hospital admissions and deaths - almost all from unvaccinated. and similar statistics now even with the delta variant.
(2) Phase III kicked out 300 sick people. We would need, as always in these things, to see the details. Why were those people kicked out? Did they correlate with those given the vaccination? How did that number compare with the total getting sick ovr the course of the trial? Perhaps you could link your sources so these details could be addressed.
(3) Israeli deaths increased exponentially at start of vaccination.
That is surely expected - with a 100% effective vaccine, COVID deaths do normally increase expeonentially with R > 1. Until a large number of people (> 50% of population) are vaccinated the protetcive effect (linear) is insigniifcant compared with the exponential infection increase. (There is another protective effect, R goes down as fraction vaccinated increases - but this also is small until a significant fraction of people have been vaccinated).
And for your memory: About half of UK got Astra Zeneca...
Relative efficacy of Astra Zeneca vs Pfizer (but only after one dose - so much lower than two-dose effectiveness)
The phase 3 trials substantiating authorization of the currently available COVID-19 vaccines are well known — but how effective are these vaccines in real life, especially when just a single dose is given (as has been advocated in the U.K.) to permit broader coverage with limited supplies? Investigators conducted a population-based study of the effectiveness of COVID-19 vaccination in England between December 8, 2020, and February 19, 2021, when the B1.1.7 variant emerged. SARS-CoV-2 PCR test results in 156,930 adults aged ≥70 were linked with national vaccination and mortality registries and hospital admissions data.
When vaccination status was assessed in individuals testing positive for SARS-CoV-2 (44,590; 28%) compared with those testing negative (112,340; 72%), a protective effect was seen in Pfizer/BioNTech BNT162b2 recipients 10–13 days after vaccination, reaching 61% effectiveness after 28 days. For those who received the AstraZeneca vaccine (ChAdOx1-S), protective effects emerged 14–20 days after vaccination, reaching 60% effectiveness after 28 days. Among individuals aged ≥80 who received BNT162b2, vaccine effectiveness was 70% 28 days after the first dose and 89% 14 days after the second dose. If infection developed despite vaccination ≥14 days previously, incidence of emergency hospital admission was 43% lower with BNT162b2 and 37% lower with ChAdOx1-S. For BNT162b2, mortality risk within 21 days was reduced by 53%.
For delta variant two doses are obviously needed, the data is not yet all in- but it looks as though pfizer beats astaZeneca:
However, another recent study carried out by Public Health England (PHE) found that for the period from 5 April to 16 May the Pfizer vaccine was 88 per cent effective against symptomatic disease from the Delta variant two weeks after the second dose.
This was compared to 93 per cent effectiveness against the Alpha (B.1.1.7) variant first found in Kent.
The same study also found that two doses of the AstraZeneca vaccine were 60 per cent effective against symptomatic disease from the Delta variant, compared to 66 per cent effectiveness against the Alpha variant.
Re credibility of sources. I have no reason to think PHE (Public health England) here in the UK is in the pocket of "big pharma" or interested in anything except reducing the load on the NHS. And accusing the UK scientists conducting these studies of some systemic corruption that would kill a significant part of the UK population is both far-fetched and also libellous?